Immunome, Inc. (NASDAQ: IMNM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
23.93
+0.47+2.00%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -3.08 | Insider Own | 8.63% | Shs Outstand | 95.60M | Perf Week | -4.16% |
| Market Cap | 2.29B | Forward P/E | - | EPS next Y | -2.47 | Insider Trans | -9.75% | Shs Float | 79.25M | Perf Month | -13.17% |
| Enterprise Value | 1.77B | PEG | - | EPS next Q | -0.64 | Inst Own | - | Short Float | 19.73% | Perf Quarter | 29.14% |
| Income | -212.00M | P/S | 175.97 | EPS this Y | 24.62% | Inst Trans | - | Short Ratio | 11.27 | Perf Half Y | 16.05% |
| Sales | 13.00M | P/B | 4.36 | EPS next Y | -6.21% | ROA | -44.98% | Short Interest | 15.63M | Perf YTD | 11.41% |
| Book/sh | 5.49 | P/C | 4.40 | EPS next 5Y | - | ROE | -50.56% | 52W High | 30.06 -20.39% | Perf Year | 163.26% |
| Cash/sh | 5.44 | P/FCF | - | EPS past 3/5Y | - | ROIC | -51.06% | 52W Low | 8.93 167.97% | Perf 3Y | 221.21% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.26% 4.32% | Perf 5Y | 31.99% |
| Dividend TTM | - | EV/Sales | 136.35 | EPS Y/Y TTM | 38.40% | Oper. Margin | 0.00% | ATR (14) | 1.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 15.08 | Sales Y/Y TTM | 44.44% | Profit Margin | 0.00% | RSI (14) | 37.57 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.08 | EPS Q/Q | -30.00% | SMA20 | -10.27% | Beta | 2.51 | Target Price | 35.25 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | -100.00% | SMA50 | -5.29% | Rel Volume | 0.69 | Prev Close | 23.46 |
| Employees | 247 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | 5.95% | Avg Volume | 1.29M | Price | 23.93 |
| IPO Date | Oct 02, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -26.51% - | Net Debt/EBITDA | 0.85 | Volume | 890,751 | Change | 2.00% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-12-26 | Reiterated | Wedbush | Outperform | $33 → $35 |
| May-28-26 | Reiterated | Barclays | $36 | |
| May-28-26 | Reiterated | Truist Securities | Buy | $36 → $37 |
| May-15-26 | Reiterated | Leerink Partners | Outperform | $40 → $33 |
| Feb-12-26 | Initiated | H.C | Buy | $40 |
| Dec-16-25 | Reiterated | Evercore ISI Group | Outperform | $18 → $40 |
| Dec-16-25 | Reiterated | Lake Street | Buy | $32 |
| Dec-15-25 | Reiterated | Leerink Partners | $38 → $40 | |
| Dec-01-25 | Initiated | Truist | Buy | $36 |
| Nov-17-25 | Reiterated | Stephens & Co. | Overweight | $33 |
Latest News· Times ET
Sep-10-26
Sep-09-26
Sep-09-2604:02AM
Sep-08-26
Sep-08-2612:02PM
Sep-02-26
Sep-02-2603:45AM
Aug-17-26
Aug-17-2606:04AM
Aug-16-26
Aug-16-2609:00PM
Aug-13-26
Aug-13-2611:24AM
Aug-12-26
Aug-11-26
Aug-11-2612:02PM
Aug-06-26
Aug-06-2612:02PM
Aug-05-26
Jul-23-26
Jul-23-2611:58PM
Jul-21-26
Jul-20-26
Jul-20-2603:30AM
Jul-12-26
Company
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 13 | 7 | 9 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1 | 3 | 0 | — | — | — | — | — | — | |
| Gross Profit | 12 | 4 | 9 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 41 | 44 | 33 | — | — | — | — | — | — | |
| Research and Development | 162 | 174 | 130 | — | — | — | — | — | — | |
| Other Operating Expense | 34 | 0 | 152 | — | — | — | — | — | — | |
| Operating Income | -225 | -214 | -306 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 12 | 2 | 13 | — | — | — | — | — | — | |
| Net Income Before Taxes | -212 | -212 | -293 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -212 | -212 | -293 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -212 | -212 | -293 | — | — | — | — | — | — | |
| Net Income | -212 | -212 | -293 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.08 | -2.43 | -5.00 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.08 | -2.43 | -5.00 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.08 | -2.43 | -5.00 | — | — | — | — | — | — | |
| EBITDA | -182 | -209 | -151 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 160.15 | 266.97 | 69.62 | — | — | — | — | — | — | |
| Gross Margin | 92.31 | 57.14 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -1,730.77 | -3,057.14 | -3,400.00 | — | — | — | — | — | — | |
| Net Margin | -1,630.77 | -3,028.57 | -3,255.56 | — | — | — | — | — | — | |
| Shares Outstanding | 87 | 87 | 59 | — | — | — | — | — | — | |
| Market Capitalization | 2,082 | 1,869 | 627 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Higgins Jack | Chief Scientific Officer | Sep 11 '26 | Option Exercise | 1.35 | 36,000 | 48,600 | 133,840 | Sep 15 |
| Higgins Jack | Chief Scientific Officer | Sep 11 '26 | Sale | 25.32 | 13,200 | 334,224 | 65,050 | Sep 15 |
| Barchas Isaac | Director | Aug 12 '26 | Sale | 27.25 | 11,048 | 301,058 | 92,211 | Aug 12 |
| Barchas Isaac | Director | Aug 11 '26 | Sale | 26.23 | 62,291 | 1,633,893 | 0 | Aug 12 |
| Barchas Isaac | Director | Aug 10 '26 | Sale | 26.07 | 10,125 | 263,959 | 62,291 | Aug 12 |
| Barchas Isaac | Director | Aug 07 '26 | Sale | 26.06 | 15,248 | 397,363 | 72,416 | Aug 10 |
| Barchas Isaac | Director | Aug 06 '26 | Sale | 26.06 | 20,840 | 543,090 | 87,664 | Aug 10 |
| Horn Kinney | CHIEF BUSINESS OFFICER | Aug 04 '26 | Sale | 25.09 | 90,616 | 2,273,555 | 0 | Aug 06 |
| Horn Kinney | CHIEF BUSINESS OFFICER | Aug 04 '26 | Option Exercise | 11.89 | 90,616 | 1,077,379 | 90,616 | Aug 06 |
| Horn Kinney | CHIEF BUSINESS OFFICER | Jul 07 '26 | Sale | 25.00 | 1,092 | 27,300 | 0 | Jul 09 |
| Horn Kinney | CHIEF BUSINESS OFFICER | Jul 07 '26 | Option Exercise | 12.92 | 1,092 | 14,109 | 1,092 | Jul 09 |
| Barchas Isaac | Director | Jul 07 '26 | Sale | 24.20 | 16,906 | 409,125 | 108,504 | Jul 07 |
| Barchas Isaac | Director | Jul 06 '26 | Sale | 24.11 | 83,094 | 2,003,396 | 125,410 | Jul 07 |
| Lechleider Robert | Chief Medical Officer | Jul 02 '26 | Option Exercise | 8.73 | 55,000 | 480,150 | 70,805 | Jul 07 |
| Lechleider Robert | Chief Medical Officer | Jul 02 '26 | Sale | 22.62 | 55,000 | 1,244,331 | 15,805 | Jul 07 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.